1 / 11

Organization for the Assessment of Strategies for Ischemic Syndromes 6 (OASIS-6) Trial

OASIS - 6 Trial. Organization for the Assessment of Strategies for Ischemic Syndromes 6 (OASIS-6) Trial. Presented at The American College of Cardiology Scientific Session 2006 Presented by Dr. Salim Yusuf. OASIS - 6 Trial: Background.

cara
Télécharger la présentation

Organization for the Assessment of Strategies for Ischemic Syndromes 6 (OASIS-6) Trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. OASIS - 6 Trial Organization for the Assessment of Strategies for Ischemic Syndromes 6 (OASIS-6) Trial Presented at The American College of Cardiology Scientific Session 2006 Presented by Dr. Salim Yusuf

  2. OASIS - 6 Trial: Background • The goal of the trial was to evaluate treatment with fondaparinux compared with control (unfractionated heparin or placebo) among patients with STEMI. • Patients were separated into Stratum 1 (control group inelligible for UFH treatment, in other words fondaparinux was compared to placebo) and Stratum 2 (active control group was UFH) • Also, there was a PCI substudy that assessed the efficacy of fondaparinux in Stratum 1 and Stratum 2 in the primary PCI setting. Presented at ACC 2006

  3. OASIS – 6 Trial: Study Design 12,092 patients presenting with STEMI within 24 hours of symptom onset (shortened to 12 hours of symptom onset midway through trial) Randomized. Blinded. Factorial. 28% female, mean age 62 years, mean follow-up 3-6 months Stratum 2 (UFH) Stratum 1 (No UFH) UFH Fondaparinux 2.5mg/day for up to 8 days or hospital discharge Fondaparinux 2.5mg/day for up to 8 days or hospital discharge Placebo • Primary Endpoint: Composite of death or reinfarction at 30 days • Secondary Endpoint: Composite of death or reinfarction at 9 days and at final follow-up Presented at ACC2006

  4. OASIS – 6 Trial: Primary Endpoint Primary Endpoint: Death/Reinfarction (%) • The primary endpoint was lower in the fondaparinux group compared with the control group (9.7% vs.11.2%, HR 0.86, p=0.008) • The results were similar at 9 days (HR 0.83, p=0.003) and at study end (HR 0.88, p=0.008) Frequency p=0.008 p=0.008 p=0.003 Presented at ACC 2006

  5. OASIS – 6 Trial: Primary Endpoint (cont.) Reduction in Death/MI: Stratum 1 (No UFH indicated) p<0.05 Reduction in Death/MI: Stratum 2 (UFH Indicated) p=NS p=0.97 • The reduction in the primary endpoint at 30 days in the Fondaparinux group was driven by Stratum 1, where death/MI occurred less frequently among Fonda pts than Placebo (11.2 vs. 14%, HR 0.79, p<0.05) • There was no difference in Stratum 2, comparing those patients who received Fondaparinux vs those who received UFH (8.3% vs. 8.7%, HR 0.96, p=NS) Presented at ACC 2006

  6. OASIS – 6 Trial: Primary Composite Endpoint Components of Primary Composite Endpoint (%) • Among the components of the composite at 30 days, mortality was lower in the fondaparinux group compared to the control group (7.8% vs. 8.9%, HR 0.87, p=0.03). • Reinfarction was also lower in the fondaparinux group compared to the control group (2.5% vs. 3.0% HR 0.81, p=0.06). p=0.03 p=0.06 Presented at ACC 2006

  7. OASIS - 6 Trial: PCI Substudy at 30 Days Primary Endpoint of Death or MI in PCI Cohort (%) p=0.19 • There was no difference in the primary endpoint for patients who were managed with primary PCI (6.1% vs 5.1%, p=0.19). • Guiding catheter thrombosis in the primary PCI cohort occurred more often with fondaparinux compared with control (n=22 vs. n=0, p<0.001) Presented at ACC 2006

  8. OASIS - 6 Trial: PCI Substudy (cont.) Severe Bleeding at 9 days (%) p=NS • There was no difference in severe bleeding at 9 days by treatment group • (1.0% Fondaparinux vs. 1.3% control, p=NS) • Intracranial hemorrhage occurred in 0.2% in each group Presented at ACC 2006

  9. OASIS - 6 Trial: PCI Substudy (cont.) Guiding Catheter Thrombosis p<0.001 • There was a higher instance of guiding catheter thrombosis in the PCI cohort treated with fondaparinux compared to control (n=22 vs. n=0, p<0.001) Presented at ACC 2006

  10. OASIS - 6 Trial: PCI Substudy (cont.) Coronary Complications p=0.04 • Coronary complications occurred in more patients treated with fondaparinux compared to control (n=270 vs. n=225, p=0.04) • Coronary complications include abrupt closure, no reflow, dissection, new angiographic thrombus, perforation, or catheter thrombus Presented at ACC 2006

  11. OASIS – 6 Trial: Conclusions • The benefit of Fondaparinux was confined to patients in Stratum 1 where placebo or no antithrombin was administered • Fondaparinux was not superior to active control UFH • Fondaparinux was associated with a hazard in those patients who underwent PCI including guiding catheter thrombosis Presented at ACC 2006

More Related